EPI-743 reverses the progression of the pediatric mitochondrial disease-Genetically defined Leigh Syndrome

► We performed a prospective open label trial of the novel therapeutic EPI-743 for children with Leigh syndrome ► There was a statistically significant improvement in all trial outcome measurements signifying arrest and reversal of disease progression ► There were no drug related adverse events or clinical laboratory abnormalities